Owensboro Health’s Post

Immunotherapy, precision medicine, biomarkers, and pharmacist engagement...oh my! Signficant science and practice focus on delivering value and improving outcomes. Come join us for these conversations and more! Hit me up if you have questions. #oncology #IVBM #AJMC #evidencebasedmedicine #Boston #valuebasedcare

Learn more about the extensive and ongoing cancer research happening at the VA which is spotlighted this #NationalCancerPreventionMonth.   Check out the link below.  

Meet the team! 📌 Meet Netteke van Holthe, physician at My Cancer Navigator, the personal information service of the Anticancer Fund. 💡 "As a physician at My Cancer Navigator, my passion for oncology and patient care truly come together. Each day, we empower patients to regain control of their lives, offering not only essential information, but also guidance and empathy. It’s more than a job to me: it’s about positively impacting the lives of those confronted with cancer.” 💚💙 #anticancerfund #antikankerfonds #fondsanticancer #mycancernavigator

Giving via DAFs can be done now and as a bequest. Consider this approach to maximize your philanthropic planning.

https://bit.ly/4dGwY1l As we recognize Breast Cancer Awareness Month, it’s time to address the broader issue—women’s health is underfunded and under-researched. Dive into our latest article to uncover the shocking gaps in women’s healthcare—and what we can do about them. Read more: https://bit.ly/4dI6JaC #BreastCancerAwarenessMonth #WomensHealth

This weekend, the American Society of Clinical Oncology (ASCO) conference showcased ground-breaking advancements in the treatment of leukaemia and other haematological malignancies as well as a host of other cancers. A pivotal Phase 3 trial (the ASC4FIRST study) was presented, comparing the first in class drug asciminib with other tyrosine kinase inhibitors (TKIs) in newly diagnosed chronic myeloid leukaemia (CML) patients. The promising results provide evidence that asciminib could become potentially become a first-line treatment in CML, although longer- term follow up data will be needed first. Currently asciminib is available to certain CML patients if other two or more other TKIs have been tried first. Additionally, significant progress was showcased at ASCO in hematopoietic stem cell transplants. A Phase 1 study of STC-15, a METTL-3 inhibitor, showed encouraging results in patients with advanced malignancies, demonstrating safety and clinical activity. This lays the groundwork for Phase 2 trials later this year. Leukaemia UK has funded Dr Kostas Tzelepis's laboratory research at Cambridge on targeting METTL-3 in leukaemia in collaboration with STORM Therapeutics, which led this new trial. We are proud to support such pioneering laboratory work, which could help to underpin the development of potential new leukaemia treatments. https://lnkd.in/eQ3n8GnS #ASCO2024 #LeukemiaResearch #Oncology #Hematology #CancerTreatment #ClinicalTrials #InnovationInHealthcare

The American Society of Clinical Oncology (ASCO) Annual Meeting is an important event in the oncology field, bringing together top researchers, trialists and clinicians to discuss groundbreaking cancer research and innovative therapies. Held from May 31 to June 4, 2024, in Chicago, this year’s meeting continues to highlight significant advancements, with respect to newer therapies and newer approaches in cancer care. Whether it was newer therapies, the use of previously unused combinations or investigative approaches like ctDNA, it had’em all. However, it’s crucial to make such influential events more accessible to professionals from low to middle-income countries (LMICs). Providing scholarships, virtual attendance options, and enhanced partnerships can bridge the gap, ensuring broader participation and fostering global collaboration in the fight against cancer. By expanding opportunities for all, we can drive forward the mission of health for all. #ASCO2024 #Oncology #CancerResearch #GlobalHealth

Early Detection by personal responsibility. It is the best if not only way for most of us all.

Early detection saves lives! Starting from September 2021, the Hong Kong Government has launched the Breast Cancer Screening Pilot Programme to provide screening services for eligible women over a period of two years. The aim is to detect early breast cancer in women before any symptoms of breast cancer appear, so that treatment can be carried out early to prevent cancer from getting worse. The Pilot Programme is using personalized breast cancer risk assessment tools to assess the risk of developing breast cancer for women enrolled in the Woman Health Service (WHS) and provide breast cancer screening, as appropriate, at its three Women Health Centres. Upon enrolling in the WHS with an annual fee of $310, eligible women will pay $225 for MMG per episode. But in fact how many lady in HK know about this scheme and how it operates? Giving the low participation rate in the phase 1 of the project, it is needed to review together to improve through various ways including public education, screening criteria, operation, etc. We believe through meeting with various stakeholders can make a good change and Hong Kong as one of the best practice city on breast cancer prevention in the near future. #BreastCancerScreening #EarlyDetectionSavesLives #healthbureau #BreastCancerPilotScheme #CancerPrevention #CancerScreening #MammographyScreening

October is #BreastCancerAwarenessMonth 🎀 Did you know that 1 in 8 women will be diagnosed with breast cancer in her lifetime? That’s one person every 2 minutes in the U.S. 💗 Early detection is key, with a 99% 5-year relative survival rate when caught at a localized stage. Let’s stand together, support each other and spread awareness. Share this post to remind your loved ones to get screened and stay informed. Together, we can make a difference! 💪💕 #BreastCancerAwareness #EarlyDetection #SupportAndSurvive #PinkRibbon